<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26824892</article-id><article-id pub-id-type="pmc">4732606</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0141000</article-id><article-id pub-id-type="publisher-id">PONE-D-14-03994</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella Pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella Pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Bacterial Pathogens</subject><subj-group><subject>Klebsiella</subject><subj-group><subject>Klebsiella Pneumoniae</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Pneumonia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Response</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Inflammation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Klebsiella Infections</subject><subj-group><subject>Klebsiella Pneumonia</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Pneumonia</subject><subj-group><subject>Klebsiella Pneumonia</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>Neutrophils</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Bacterial Diseases</subject><subj-group><subject>Klebsiella Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cell Motility</subject><subj-group><subject>Chemotaxis</subject><subj-group><subject>Chemokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Receptor for Advanced Glycation End Products (RAGE) Serves a Protective Role during <italic>Klebsiella pneumoniae</italic> - Induced Pneumonia</article-title><alt-title alt-title-type="running-head">Role of RAGE during <italic>Klebsiellae pneumoniae</italic> Induced Pneumonia</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Achouiti</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Vos</surname><given-names>Alex F.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>van &#x02018;t Veer</surname><given-names>Cornelis</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Florquin</surname><given-names>Sandrine</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tanck</surname><given-names>Michael W.</given-names></name><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nawroth</surname><given-names>Peter P.</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bierhaus</surname><given-names>Angelika</given-names></name><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>van der Poll</surname><given-names>Tom</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>van Zoelen</surname><given-names>Marieke A. D.</given-names></name><xref ref-type="aff" rid="aff006"><sup>6</sup></xref><xref ref-type="aff" rid="aff007"><sup>7</sup></xref><xref ref-type="aff" rid="aff008"><sup>8</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Center for Infection and Immunity Amsterdam (CINIMA), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Center for Experimental and Molecular Medicine (CEMM), Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Internal Medicine and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Laboratory of Biomedical Science, Feinstein Institute for Medical Research, North Shore Long Island University Hospital, Manhassat, New York, United States of America</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Division of Internal Medicine and Infectious Diseases, University Medical Center of Utrecht, Utrecht, the Netherlands</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>Laboratory of Translational Immunology (LTI), University Medical Center of Utrecht, Utrecht, the Netherlands</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Wu</surname><given-names>Min</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of North Dakota, UNITED STATES</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: AA AFdV CV TvdP MADvZ. Performed the experiments: AA AFdV CV SF MADvZ. Analyzed the data: AA AFdV CV PPN AB SF MWT TvdP MADvZ. Contributed reagents/materials/analysis tools: PPN AB MWT. Wrote the paper: AA TvdP MADvZ.</p></fn><corresp id="cor001">* E-mail: <email>M.A.D.vanZoelen@umcutrecht.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>1</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>1</issue><elocation-id>e0141000</elocation-id><history><date date-type="received"><day>23</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>2</day><month>10</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Achouiti et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Achouiti et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0141000.pdf"/><abstract><p><italic>Klebsiella</italic> species is the second most commonly isolated gram-negative organism in sepsis and a frequent causative pathogen in pneumonia. The receptor for advanced glycation end products (RAGE) is expressed on different cell types and plays a key role in diverse inflammatory responses. We here aimed to investigate the role of RAGE in the host response to <italic>Klebsiella</italic> (<italic>K</italic>.) <italic>pneumoniae</italic> pneumonia and intransally inoculated <italic>rage</italic> gene deficient (RAGE<sup>-/-</sup>) and normal wild-type (Wt) mice with <italic>K</italic>. <italic>pneumoniae</italic>. <italic>Klebsiella</italic> pneumonia resulted in an increased pulmonary expression of RAGE. Furthermore, the high-affinity RAGE ligand high mobility group box-1 was upregulated during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia. RAGE deficiency impaired host defense as reflected by a worsened survival, increased bacterial outgrowth and dissemination in RAGE<sup>-/-</sup> mice. RAGE<sup>-/-</sup> neutrophils showed a diminished phagocytosing capacity of live <italic>K</italic>. <italic>pneumoniae in vitro</italic>. Relative to Wt mice, RAGE<sup>-/-</sup> mice demonstrated similar lung inflammation, and slightly elevated&#x02014;if any&#x02014;cytokine and chemokine levels and unchanged hepatocellular injury. In addition, RAGE<sup>-/-</sup> mice displayed an unaltered response to intranasally instilled <italic>Klebsiella</italic> lipopolysaccharide (LPS) with respect to pulmonary cell recruitment and local release of cytokines and chemokines. These data suggest that (endogenous) RAGE protects against <italic>K</italic>. <italic>pneumoniae</italic> pneumonia. Also, they demonstrate that RAGE contributes to an effective antibacterial defense during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia, at least partly via its participation in the phagocytic properties of professional granulocytes. Additionally, our results indicate that RAGE is not essential for the induction of a local and systemic inflammatory response to either intact <italic>Klebsiella</italic> or <italic>Klebsiella</italic> LPS.</p></abstract><funding-group><funding-statement>This work was supported by a VENI grant in the field of biomedical sciences from the Netherlands Organisation for Scientific Research (NWO) and by a Clinical Research Talent Fellowship grant from the UMCU, both to MADvZ, and by a grant from the Deutsche Forschungsgemeinschaft (SFB405 to PPN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="2"/><page-count count="15"/></counts></article-meta></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p><italic>Klebsiella</italic> (<italic>K</italic>.) <italic>pneumoniae</italic> is a major cause of pneumonia [<xref rid="pone.0141000.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0141000.ref002" ref-type="bibr">2</xref>] and the second most common cause of Gram-negative sepsis [<xref rid="pone.0141000.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0141000.ref004" ref-type="bibr">4</xref>]. <italic>Klebsiella</italic> infection presents a significant burden on healthcare and is asociated with high morbidity and mortality rates. The increasing microbial resistance of <italic>Klebsiella</italic> species to last-resort antibiotics, resulting in therapy failure and even more higher mortality rates, is an issue of major concern [<xref rid="pone.0141000.ref005" ref-type="bibr">5</xref>]. Therefore it is important to gain more insight into the pathogenesis of <italic>K</italic>. <italic>pneumoniae</italic> pneumonia in order to develop new treatment strategies.</p><p>The receptor for advanced glycation end products (RAGE) is a multiligand receptor of the immunoglobulin (Ig) superfamily. RAGE is expressed in all tissues on a wide range of cell types, including cells involved in the innate and adaptive immune system and it plays a key role in diverse inflammatory processes [<xref rid="pone.0141000.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0141000.ref007" ref-type="bibr">7</xref>]. First of all, RAGE can detect endogenous innate danger signals, also named damage-associated molecular patterns (DAMPs) or alarmins, which are structurally diverse proteins rapidly released by the host itself during infection to warn the host for imminent danger [<xref rid="pone.0141000.ref008" ref-type="bibr">8</xref>]. Engagement of these and other ligands to RAGE can induce inflammatory responses via activation of several intracellular signaling cascades, including the nuclear factor-&#x003ba;B pathway [<xref rid="pone.0141000.ref009" ref-type="bibr">9</xref>]. High mobility group box-1 (HMGB1) and S100A12 (or myeloid related protein-6, MRP-6) are known DAMPs that induce an inflammatory response upon binding to RAGE [<xref rid="pone.0141000.ref010" ref-type="bibr">10</xref>&#x02013;<xref rid="pone.0141000.ref012" ref-type="bibr">12</xref>]. Previously, it was demonstrated that HMGB1 and S100A12 are released in patients with severe sepsis [<xref rid="pone.0141000.ref013" ref-type="bibr">13</xref>&#x02013;<xref rid="pone.0141000.ref017" ref-type="bibr">17</xref>] and HMGB1 in mice with experimentally induced abdominal sepsis [<xref rid="pone.0141000.ref018" ref-type="bibr">18</xref>]. In addition, RAGE can function as an endothelial adhesion receptor for the leukocyte integrin CD11b/CD18, thereby promoting leukocyte recruitment to the site of infection [<xref rid="pone.0141000.ref019" ref-type="bibr">19</xref>].</p><p>In <italic>in vivo</italic> models of abdominal polymicrobial sepsis, RAGE<sup>-/-</sup> mice demonstrated a diminished lethality after cecal ligation and puncture (CLP) [<xref rid="pone.0141000.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0141000.ref021" ref-type="bibr">21</xref>]. Moreover, anti-RAGE therapy yielded an enhanced survival even when the anti-RAGE antibodies were administered 24 hours after CLP in mice receiving antibiotic treatment [<xref rid="pone.0141000.ref021" ref-type="bibr">21</xref>]. In an abdominal sepsis model that is more suitable to study the influence of an intervention on bacterial outgrowth and dissemination, RAGE contributed to an effective antibacterial defense, thereby limiting the accompanying inflammatory response [<xref rid="pone.0141000.ref022" ref-type="bibr">22</xref>].</p><p>Earlier, we found that RAGE deficient (<sup>-/-</sup>) mice are protected against pneumonia caused by the Gram-positive bacterium <italic>Streptococcus</italic> (<italic>S</italic>.) <italic>pneumoniae</italic> as reflected by an enhanced survival, diminished outgrowth at the primary site of infection and a decreased spreading of bacteria to other body compartments together with reduced lung damage [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>]. In accordance, Christaki et al. demonstrated that treatment with anti-RAGE antibodies combinated with the antibiotic moxifloxacin protects mice from <italic>S</italic>. <italic>pneumoniae</italic> pneumonia induced mortality [<xref rid="pone.0141000.ref024" ref-type="bibr">24</xref>]. Whereas the Gram-positive <italic>S</italic>. <italic>pneumoniae</italic> is the most commonly isolated pathogen in patients with community-acquired pneumonia, the Gram-negative <italic>K</italic>. <italic>pneumoniae</italic> is a causative organism in both community-acquired and nosocomial pneumonia [<xref rid="pone.0141000.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0141000.ref026" ref-type="bibr">26</xref>]. We here sought to determine the role of RAGE in Gram-negative pneumonia-originating sepsis caused by <italic>K</italic>. <italic>pneumoniae</italic>.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and Methods</title><sec id="sec003"><title>Animals</title><p>10-week-old male RAGE<sup>-/-</sup> mice were generated as previously described [<xref rid="pone.0141000.ref027" ref-type="bibr">27</xref>] and backcrossed ten times to a C57Bl/6 background. Wild-type C57Bl/6 mice were obtained from Harlan Sprague Dawley Inc. (Horst, The Netherlands). Experimental groups were age- and sex matched and housed in the Animal Research Institute Amsterdam under standard care.</p></sec><sec id="sec004"><title>Ethics statement</title><p>This study ware carried out in concordance with the &#x0201c;Wet op de Dierproeven&#x0201d; in the Netherlands. The Institutional Animal Care and Use Committee of the Academic Medical Center, University of Amsterdam, approved all experiments. All efforts were made to minimize suffering. Induction of pneumonia or sterile lung inflammation happened under isoflurane anaesthesia. In the survival study, mice died either as a direct result of the intervention or by humanely euthanization by cervical dislocation when they met human endpoints as reflected by clinical criteria such as signs of excessive weight loss, lethargy and severe unrelieved distress. Clinical signs of distress and mortality were observed two to four times per day during.</p></sec><sec id="sec005"><title>Experimental study design</title><p><italic>K</italic>. <italic>pneumoniae</italic> pneumonia and <italic>Klebsiella</italic> lipopolysaccharide (LPS)-induced lung inflammation were induced as reported previously [<xref rid="pone.0141000.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0141000.ref029" ref-type="bibr">29</xref>]. Wild-type and RAGE<sup>-/-</sup> mice were inoculated intranasally with 1 x 10<sup>4</sup> CFUs <italic>K</italic>. <italic>pneumoniae</italic>. Mice were either euthanized at predefined time points or (in survival studies) monitored for 2 weeks. Preparation of lung and liver homogenates, histology, RAGE staining and bronchoalveolar lavage were performed as described before [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0141000.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0141000.ref029" ref-type="bibr">29</xref>]. Enzyme-linked immunosorbence and cytometric beads multiplex assays, measurements of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and cell counts were performed as described before [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0141000.ref028" ref-type="bibr">28</xref>,<xref rid="pone.0141000.ref029" ref-type="bibr">29</xref>].</p></sec><sec id="sec006"><title>Phagocytosis assays</title><p>Phagocytosis of <italic>K</italic>. <italic>pneumoniae</italic> was determined as described before [<xref rid="pone.0141000.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0141000.ref030" ref-type="bibr">30</xref>]. In brief, a concentrated <italic>K</italic>. <italic>pneumoniae</italic> preparation was treated for 60 min at 37&#x000b0;C with 50 &#x003bc;g/mL mitomycine-C (Sigma-Aldrich, Zwijndrecht, the Netherlands) to prepare growth-arrested, but alive bacteria. Next, 50 &#x003bc;L of heparinized whole blood from wild-type and RAGE<sup>-/-</sup> mice was incubated at 37&#x000b0;C (<italic>n</italic> = 8 mice per group) or 4&#x000b0;C (<italic>n</italic> = 4 mice per group) with Alexa647-succinimidyl-ester (Alexa647-SE, Invitrogen, Breda, the Netherlands) labeled, growth-arrested bacteria (end concentration of 1 &#x000d7; 10<sup>7</sup> CFUs/mL) for 60 min. Phagocytosis was stopped by placing cells on ice and erythrocytes were lysed with ice-cold isotonic NH<sub>4</sub>Cl solution (155 mM NH<sub>4</sub>Cl, 10 mM KHCO<sub>3</sub>, 100 mM EDTA, pH 7.4). Neutrophils were labeled using anti-Gr-1-PE (BD Pharmingen, San Diego, CA). Cells were then washed with FACS-buffer (0.5% BSA, 0.01% NaN3, 0.35 mM EDTA in PBS) after which the degree of phagocytosis of neutrophils was determined using FACSCalibur (Becton Dickinson Immunocytometry, San Jose, CA). Phagocytosis index of each sample was calculated as follows: mean fluorescense of positive cells &#x000d7; % positive cells.</p></sec><sec id="sec007"><title>HMGB1 measurement</title><p>For Western blotting of HMGB1, bronchoalveolar lavage fluid (BALF) samples were diluted with 2x Laemmli buffer. After heating, samples were run on 15% polyacrylamide SDS gels and subsequently transferred to blotting membrane (Immobilon P (Pharmacia, Piscataway, NJ) polyvinylidene difluoride membranes). Following blocking with 5% nonfat dry milk proteins (Protifar from Nutricia, Zoetermeer, the Netherlands) in 0.1% Tween 20 phosphate buffered saline (PBS-T), membranes were washed and incubated overnight in primary antibody (rabbit anti-HMGB1 polyclonal antibody) (1 &#x003bc;g/mL, catalog no ab18256, Abcam, Cambridge, United Kingdom) in 1% nonfat dry milk proteins in PBS-T at 4&#x000b0;C. After washing with PBS-T, membranes were probed with peroxidase-labeled secondary antibodies (Cell Signaling Technology, Danvers, MA) for 1 h at room temperature in 1% bovine serum albumin in PBS-T. After washing with PBS-T, membranes were incubated with Lumi-Light<sup>Plus</sup> Western Blotting Substrate (Roche, Mijdrecht, The Netherlands) and positive bands were detected using a LAS3000 Luminescent image Analyzer dark box (Fujifilm, Tokyo, Japan).</p></sec><sec id="sec008"><title>Statistical analysis</title><p>Differences between groups were analyzed by Mann-Whitney <italic>U</italic> test. Data in the figures are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation unless indicated otherwise. For survival analysis, Kaplan-Meier analysis was performed followed by a log-rank test. <italic>P</italic> values of <italic>&#x0003c;</italic> 0.05 were considered to represent a statistically significant difference.</p></sec></sec><sec sec-type="results" id="sec009"><title>Results</title><sec id="sec010"><title>RAGE expression in the lungs</title><p>To obtain insight into constitutive and <italic>K</italic>. <italic>pneumoniae</italic>-induced RAGE expression, we performed immunohistochemical stainings of RAGE of lung tissue from healthy, uninfected wild-type mice and from wild-type mice after inoculation with <italic>K</italic>. <italic>pneumoniae</italic>. In accordance with the literature [<xref rid="pone.0141000.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0141000.ref034" ref-type="bibr">34</xref>], normal healthy mice showed extensive RAGE staining in their lungs (<xref ref-type="fig" rid="pone.0141000.g001">Fig 1A</xref>), being mainly present in the interalveolar septae in an endothelial pattern, while bronchial epithelial cells were negative for RAGE staining (<xref ref-type="fig" rid="pone.0141000.g001">Fig 1A</xref>, <italic>arrow</italic>). The specificity of the RAGE staining was confirmed by immunohistochemical analysis of lungs obtained from RAGE<sup>-/-</sup> mice, used as negative controls (<xref ref-type="fig" rid="pone.0141000.g001">Fig 1B</xref>). Lungs from <italic>K</italic>. <italic>pneumoniae</italic> infected mice displayed the same pattern of RAGE positivity as lungs from healthy wild-type mice, <italic>i</italic>.<italic>e</italic>. the interalveolar septae stained positive for RAGE staining with an endothelial pattern; however, RAGE expression was enhanced following pulmonary infection with <italic>K</italic>. <italic>pneumoniae</italic> as reflected by more intense staining (<xref ref-type="fig" rid="pone.0141000.g001">Fig 1C</xref>).</p><fig id="pone.0141000.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.g001</object-id><label>Fig 1</label><caption><title>Pulmonary expression of receptor for advanced glycation end products and of its ligand high mobility group box-1 (HMGB1) during <italic>Klebsiella pneumoniae</italic> pneumonia.</title><p>Representative view of a lung from a normal, uninfected wild-type mouse (A) displaying ubiquitous expression of RAGE on the surface of endothelium. <italic>Arrow</italic> indicates bronchial epithelium, being negative for RAGE staining. B, Absence of RAGE positivity in the lung of a RAGE<sup>-/-</sup> mouse. C, Lungs from a wild-type mouse 48 h after the inoculation of <italic>K</italic>. <italic>pneumoniae</italic>. Original magnification, x10. D, Western blot was performed for HMGB1 in brochoalveolar lavage fluid (BALF) from wild-type mice at 0, 6, 24 and 48 h after <italic>K</italic>. <italic>pneumoniae</italic> intranasal inoculation (<italic>n</italic> = 3 mice per time point).</p></caption><graphic xlink:href="pone.0141000.g001"/></fig></sec><sec id="sec011"><title>HMGB1 is increased during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia</title><p>After having shown that RAGE expression is enhanced during <italic>Klebsiella</italic> pneumonia, we next investigated whether. <italic>K</italic>. <italic>pneumoniae</italic> pneumonia is associated with release of its high-affinity ligand HMGB1 [<xref rid="pone.0141000.ref035" ref-type="bibr">35</xref>]. We previously demonstrated increased HMGB1 concentrations in BALF from the infected site of patients with community-acquired pneumonia [<xref rid="pone.0141000.ref016" ref-type="bibr">16</xref>], in BALF of patients with ventilator-associated pneumonia [<xref rid="pone.0141000.ref036" ref-type="bibr">36</xref>] and in BALF from mice intranasally infected with influenza A virus [<xref rid="pone.0141000.ref037" ref-type="bibr">37</xref>]. Relative to t = 0 h, mice with pneumonia induced by <italic>K</italic>. <italic>pneumoniae</italic> had elevated HMGB1 levels in BALF at 6, 24 and 48 h (<xref ref-type="fig" rid="pone.0141000.g001">Fig 1D</xref>).</p></sec><sec id="sec012"><title>RAGE deficiency enhances lethality due to <italic>K</italic>. <italic>pneumoniae</italic> pneumonia</title><p>To study the contribution of RAGE to the outcome of <italic>Klebsiella</italic> pneumonia, wild-type and RAGE<sup>-/-</sup> mice were intranasally inoculated with <italic>K</italic>. <italic>pneumoniae</italic> and observed for 14 days (<xref ref-type="fig" rid="pone.0141000.g002">Fig 2</xref>). While the first deaths occurred after 2 days in both strains, all RAGE<sup>-/-</sup> mice had died after 10 days, while only 50% of the wild-type mice had died at the end of the observation period (p &#x0003c; 0.05). Thus, RAGE deficiency rendered mice more susceptible to <italic>K</italic>. <italic>pneumoniae</italic> induced death.</p><fig id="pone.0141000.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.g002</object-id><label>Fig 2</label><caption><title>Increased mortality of receptor for advanced glycation end products deficient (RAGE<sup>-/-</sup>) mice during <italic>Klebsiella pneumoniae</italic> pneumonia.</title><p>Survival of wild-type and RAGE<sup>-/-</sup> mice after intranasal inoculation with 1 x 10<sup>4</sup> CFUs <italic>K</italic>. <italic>pneumoniae</italic>. Mortality was assessed for 14 days (<italic>n</italic> = 13&#x02013;14 mice per genotype).</p></caption><graphic xlink:href="pone.0141000.g002"/></fig></sec><sec id="sec013"><title>RAGE deficiency facilitates early bacterial outgrowth and dissemination</title><p>To obtain insight in the mechanism underlying the higher mortaility of the RAGE<sup>-/-</sup> mice, we repeated this experiment and sacrificed mice 24 and 48 h after infection (<italic>i</italic>.<italic>e</italic>. directly before the first mice started dying) to enumerate bacterial counts in lungs, blood, liver and spleen. At 24 h after infection, bacterial outgrowth in the lungs were similar in wild-type and RAGE<sup>-/-</sup> mice. However, after 48 h, the number of <italic>Klebsiella</italic> CFUs was higher in the lungs of RAGE<sup>-/-</sup> mice when compared to the wild-type mice (<xref ref-type="fig" rid="pone.0141000.g003">Fig 3A</xref>; p &#x0003c; 0.05). At 24 h, significantly increased CFU counts were recovered from blood, liver and spleen harvested from the RAGE<sup>-/-</sup> mice compared to wild-type mice. Liver homogenates from RAGE<sup>-/-</sup> mice showed increased bacterial loads at 48 h as well (<xref ref-type="fig" rid="pone.0141000.g003">Fig 3B&#x02013;3D</xref>; all p &#x0003c; 0.05). Thus, RAGE limits the outgrowth of <italic>K</italic>. <italic>pneumoniae</italic> in the lungs and the dissemination to the blood stream and distant organs.</p><fig id="pone.0141000.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.g003</object-id><label>Fig 3</label><caption><title>Receptor for advanced glycation end products deficiency enhances local bacterial outgrowth and dissemination during <italic>Klebsiella pneumoniae</italic> pneumonia <italic>in vivo</italic> and reduces <italic>in vitro</italic> phagocytosis of <italic>Klebsiella pneumoniae</italic> by neutrophils.</title><p>Bacterial loads in lung homogenate (A), blood (B), liver (C) and spleen (D) were determined in wild-type and RAGE<sup>-/-</sup> mice 24 and 48 h after intranasal inoculation 1 x 10<sup>4</sup> CFUs <italic>K</italic>. <italic>pneumoniae</italic>. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation of 8&#x02013;10 mice per genotype at each time point. E, Phagocytosis of growth-arrested viable Alexa647-SE labeled <italic>Klebsiella pneumoniae</italic> of neutrophils from wild type and RAGE<sup>-/-</sup> mice at 37&#x000b0;C or 4&#x000b0;C. Phagocytosis was quantified as described in the Methods section. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation (of 4 mice for 4&#x000b0;C and 8 mice 37&#x000b0;C) per genotype. * p &#x0003c; 0.05, compared with wild-type mice.</p></caption><graphic xlink:href="pone.0141000.g003"/></fig></sec><sec id="sec014"><title>RAGE deficiency results in a decreased phagocytosis of <italic>K</italic>. <italic>pneumoniae</italic> by neutrophils</title><p>The increased bacterial load in RAGE<sup>-/-</sup> mice could be caused by an intrinsic defect of RAGE<sup>-/-</sup> cells to phagocytose <italic>K</italic>. <italic>pneumoniae</italic>. To investigate this possibility we harvested whole blood from uninfected wild-type and RAGE<sup>-/-</sup> mice and compared the capacity of neutrophils to phagocytose Alexa647-succinimidyl-ester labeled, but growth-arrested viable <italic>K</italic>. <italic>pneumoniae</italic>. RAGE<sup>-/-</sup> neutrophils displayed a decreased ability to phagocytose <italic>K</italic>. <italic>pneumoniae</italic> (<xref ref-type="fig" rid="pone.0141000.g003">Fig 3E</xref>).</p></sec><sec id="sec015"><title>RAGE deficiency does not impact on lung inflammation during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia</title><p>Considering that RAGE signaling results in sustained cellular activation we were interested to study the role of RAGE in lung inflammation during <italic>Klebsiella</italic> pneumonia. Thus, we analyzed lung tissue slides obtained from wild-type and RAGE<sup>-/-</sup> mice 24 and 48 h after infection. At both time points, both mouse strains displayed interstitial inflammation together with vasculitis, peri-bronchitis, edema and pleuritis (<xref ref-type="fig" rid="pone.0141000.g004">Fig 4A&#x02013;4D</xref>). Importantly, in contrast to our expectation, the extent of lung inflammation, as determined by the semi-quantitative scoring system, analyzing the severity of vasculitis, bronchitis, edema and pleuritis, was not different between wild-type and RAGE<sup>-/-</sup> mice (<xref ref-type="fig" rid="pone.0141000.g004">Fig 4E</xref>). In addition, myeloperoxidase (MPO) concentrations in lung homogenates of both mouse strains were similar at both time points (<xref ref-type="fig" rid="pone.0141000.g004">Fig 4F</xref>), indicating that RAGE deficiency did not influence neutrophil recruitment. Together these data suggest that RAGE does not play a significant role in the lung inflammation that accompanies <italic>Klebsiella</italic> pneumonia.</p><fig id="pone.0141000.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.g004</object-id><label>Fig 4</label><caption><title>Unchanged lung inflammation during <italic>Klebsiella</italic> pneumonia.</title><p>Wild-type and RAGE<sup>-/-</sup> mice were inoculated intranasally with 1 x 10<sup>4</sup> CFUs <italic>K</italic>. <italic>pneumoniae</italic>. Representative hematoxylin-eosin stainings of lung tissue at 24 (A and B) and 48 (C and D) h post inoculation in wild-type (A and C) and RAGE<sup>-/-</sup> (B and D) mice. Original magnification, x20. E, Graphical representation of the degree of lung inflammation at 24 and 48 h. F, Myeloperoxidase (MPO) levels in lung tissues. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation of 8&#x02013;10 mice per genotype at each time point. * p &#x0003c; 0.05, compared with wild-type mice.</p></caption><graphic xlink:href="pone.0141000.g004"/></fig></sec><sec id="sec016"><title>Cytokine and chemokine levels</title><p>In pulmonary infection, cytokine and chemokine production is an important factor in the host immune response [<xref rid="pone.0141000.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0141000.ref039" ref-type="bibr">39</xref>]. We determined the influence of RAGE deficiency on pulmonary and systemic cytokine and chemokine concentrations during <italic>Klebsiella</italic> pneumonia. Levels of the cytokines TNF-&#x003b1;, IL-6, MCP-1 and IL-10 and of chemokines KC and MIP-2 did not differ between the two mouse strains at 24 h. At 48 h, MCP-1 and KC concentrations were increased in the lungs of the RAGE<sup>-/-</sup> mice (<xref rid="pone.0141000.t001" ref-type="table">Table 1</xref>; p &#x0003c; 0.05). In plasma, TNF-&#x003b1;, IL-6 and MCP-1 levels were similar between the two genotypes at both time points, while IL-10 was elevated in the RAGE<sup>-/-</sup> mice at 48 h (<xref rid="pone.0141000.t001" ref-type="table">Table 1</xref>; p &#x0003c; 0.05).</p><table-wrap id="pone.0141000.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.t001</object-id><label>Table 1</label><caption><title>Cytokine and chemokine levels in lung homogenate and plasma 24 and 48 h after intanasal administration of <italic>Klebsiella pneumoniae</italic>.</title></caption><alternatives><graphic id="pone.0141000.t001g" xlink:href="pone.0141000.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" colspan="5" rowspan="1">Cytokine levels, mean pg/mL &#x000b1; SE</th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1">24 h</th><th align="center" colspan="2" rowspan="1">48 h</th></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">wild-type mice</th><th align="center" rowspan="1" colspan="1">RAGE<sup>-/-</sup> mice</th><th align="center" rowspan="1" colspan="1">wild-type mice</th><th align="center" rowspan="1" colspan="1">RAGE<sup>-/-</sup> mice</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"/><td align="center" colspan="4" rowspan="1"><bold>Lung homogenate (pg/mL)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="center" rowspan="1" colspan="1">724 &#x000b1; 187</td><td align="center" rowspan="1" colspan="1">446 &#x000b1; 66</td><td align="center" rowspan="1" colspan="1">1,679 &#x000b1; 932</td><td align="center" rowspan="1" colspan="1">5,151 &#x000b1; 1617</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">1348 &#x000b1; 252</td><td align="center" rowspan="1" colspan="1">723 &#x000b1; 240</td><td align="center" rowspan="1" colspan="1">706 &#x000b1; 301</td><td align="center" rowspan="1" colspan="1">844 &#x000b1; 223</td></tr><tr><td align="left" rowspan="1" colspan="1">MCP-1</td><td align="center" rowspan="1" colspan="1">6172 &#x000b1; 381</td><td align="center" rowspan="1" colspan="1">6006 &#x000b1; 444</td><td align="center" rowspan="1" colspan="1">2,861 &#x000b1; 282</td><td align="center" rowspan="1" colspan="1">4,838 &#x000b1; 623<xref ref-type="table-fn" rid="t001fn003"><sup>b</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">IL-10</td><td align="center" rowspan="1" colspan="1">545 &#x000b1; 99</td><td align="center" rowspan="1" colspan="1">482 &#x000b1; 50</td><td align="center" rowspan="1" colspan="1">26 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">32 &#x000b1; 6</td></tr><tr><td align="left" rowspan="1" colspan="1">KC</td><td align="center" rowspan="1" colspan="1">13991 &#x000b1; 1847</td><td align="center" rowspan="1" colspan="1">13026 &#x000b1; 1851</td><td align="center" rowspan="1" colspan="1">11,257 &#x000b1; 2,251</td><td align="center" rowspan="1" colspan="1">20,478 &#x000b1; 3,372<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></td></tr><tr><td align="left" rowspan="1" colspan="1">MIP-2</td><td align="center" rowspan="1" colspan="1">8082 &#x000b1; 1818</td><td align="center" rowspan="1" colspan="1">11298 &#x000b1; 2300</td><td align="center" rowspan="1" colspan="1">12,085 &#x000b1; 4,367</td><td align="center" rowspan="1" colspan="1">7,548 &#x000b1; 1,467</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" colspan="4" rowspan="1"><bold>Plasma (pg/mL)</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="center" rowspan="1" colspan="1">87 &#x000b1; 30</td><td align="center" rowspan="1" colspan="1">141 &#x000b1;47</td><td align="center" rowspan="1" colspan="1">62 &#x000b1; 18</td><td align="center" rowspan="1" colspan="1">56 &#x000b1; 26</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">211 &#x000b1; 49</td><td align="center" rowspan="1" colspan="1">211 &#x000b1; 58</td><td align="center" rowspan="1" colspan="1">277 &#x000b1; 159</td><td align="center" rowspan="1" colspan="1">478 &#x000b1; 157</td></tr><tr><td align="left" rowspan="1" colspan="1">MCP-1</td><td align="center" rowspan="1" colspan="1">827 &#x000b1; 188</td><td align="center" rowspan="1" colspan="1">1,777 &#x000b1; 444</td><td align="center" rowspan="1" colspan="1">519 &#x000b1; 139</td><td align="center" rowspan="1" colspan="1">526 &#x000b1; 231</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-10</td><td align="center" rowspan="1" colspan="1">14 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">21 &#x000b1; 3</td><td align="center" rowspan="1" colspan="1">1 &#x000b1; 1</td><td align="center" rowspan="1" colspan="1">8 &#x000b1; 4<xref ref-type="table-fn" rid="t001fn002"><sup>a</sup></xref></td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Data are means &#x000b1; SE of 8&#x02013;10 mice/group at 24 or 48 h after intranasal instillation of 1 x 10<sup>4</sup> CFU <italic>K</italic>. <italic>pneumoniae</italic>. SE, standard error; RAGE<sup>-/-</sup>, receptor for advanced glycation end products gene deficient; TNF, tumor necrosis factor; IL, interleukin; MCP, monocyte chemoattractant protein-1; KC, keratinocyte-derived chemokine; MIP, macrophage inflammatory protein.</p></fn><fn id="t001fn002"><p><sup>a</sup> P &#x0003c; .05, compared with wild-type mice.</p></fn><fn id="t001fn003"><p><sup>b</sup> P &#x0003c; .01, compared with wild-type mice.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec017"><title>Wild-type and RAGE<sup>-/-</sup> mice display similar hepatocellular injury</title><p>This model of <italic>Klebsiella</italic> pneumonia is associated with hepatocellular injury [<xref rid="pone.0141000.ref028" ref-type="bibr">28</xref>]. Considering the enhanced lethality and sustained elevated bacterial loads in liver homogenates in RAGE<sup>-/-</sup> mice, we were interested to examine the extent of hepatocellular injury in both mouse strains (<xref ref-type="fig" rid="pone.0141000.g005">Fig 5</xref>). At 24 h after infection, neither RAGE<sup>-/-</sup> nor wild-type mice demonstrated elevated plasma concentrations of AST or ALT. At 48 h post infection, both mouse strains had strongly elevated plasma transaminase levels; although these levels tended to be higher in RAGE<sup>-/-</sup> mice, the differences with wild-type mice did not reach statistical significance.</p><fig id="pone.0141000.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.g005</object-id><label>Fig 5</label><caption><title>Hepatocellular injury during <italic>Klebsiella pneumoniae</italic> pneumonia.</title><p>Wild-type and RAGE<sup>-/-</sup> mice were inoculated intranasally with 1 x 10<sup>4</sup> CFUs <italic>K</italic>. <italic>pneumoniae</italic> and sacrificed after 24 and 48 h. Aspartate aminotransferase (AST, A) and alanine aminotransferase (ALT, B) in plasma of wild-type and RAGE<sup>-/-</sup> mice. Data are expressed as box-and-whisker diagrams depicting the smallest observation, lower quartile, median, upper quartile and largest observation of 8&#x02013;10 mice per genotype at each time point.</p></caption><graphic xlink:href="pone.0141000.g005"/></fig></sec><sec id="sec018"><title>RAGE<sup>-/-</sup> mice demonstrate an unchanged inflammatory response to <italic>K</italic>. <italic>pneumoniae</italic> LPS</title><p>In light of the strong expression of RAGE in the lung and its reported role as a receptor mediating proinflammatory effects, we were surprised to find unaltered lung inflammation and (if anything) higher cytokine levels in RAGE<sup>-/-</sup> mice during <italic>Klebsiella</italic> pneumonia. To obtain further evidence for a modest role of RAGE in the induction of lung inflammation in response to a Gram-negative bacterium, we compared the inflammatory response to <italic>Klebsiella</italic> LPS, administered via the airways, in wild-type and RAGE<sup>-/-</sup> mice. In these studies we harvested BALF 6 h after <italic>Klebsiella</italic> LPS administration considering that this time point is representative for examining LPS responses in the pulmonary compartment [<xref rid="pone.0141000.ref040" ref-type="bibr">40</xref>&#x02013;<xref rid="pone.0141000.ref042" ref-type="bibr">42</xref>]. In line with the observations during respiratory tract infection with live <italic>K</italic>. <italic>pneumoniae</italic> in the current study, RAGE<sup>-/-</sup> mice displayed an unaltered response to intranasally instilled <italic>Klebsiella</italic> LPS with respect to pulmonary cell recruitment and local release of cytokines and chemokines (<xref rid="pone.0141000.t002" ref-type="table">Table 2</xref>).</p><table-wrap id="pone.0141000.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0141000.t002</object-id><label>Table 2</label><caption><title>Cell counts, cytokine and chemokine levels in bronchoalveolar lavalge fluid after <italic>Klebsiella</italic> lipolysaccharide inoculation.</title></caption><alternatives><graphic id="pone.0141000.t002g" xlink:href="pone.0141000.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">wild-type mice</th><th align="center" rowspan="1" colspan="1">RAGE<sup>-/-</sup> mice</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cells (x 10<sup>5</sup>/mL &#x000b1; SE)</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Total cells</td><td align="center" rowspan="1" colspan="1">5.8 &#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">8.2 &#x000b1; 1.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Neutrophils</td><td align="center" rowspan="1" colspan="1">5.5 &#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">7.7 &#x000b1; 1.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Cytokines (pg/mL &#x000b1; SE)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TNF-&#x003b1;</td><td align="center" rowspan="1" colspan="1">5561 &#x000b1; 819</td><td align="center" rowspan="1" colspan="1">6212 &#x000b1; 568</td></tr><tr><td align="left" rowspan="1" colspan="1">IL-6</td><td align="center" rowspan="1" colspan="1">2542 &#x000b1; 973</td><td align="center" rowspan="1" colspan="1">3989 &#x000b1; 583</td></tr><tr><td align="left" rowspan="1" colspan="1">KC</td><td align="center" rowspan="1" colspan="1">1327 &#x000b1; 209</td><td align="center" rowspan="1" colspan="1">870 &#x000b1; 81</td></tr><tr><td align="left" rowspan="1" colspan="1">MIP-2</td><td align="center" rowspan="1" colspan="1">661 &#x000b1; 79</td><td align="center" rowspan="1" colspan="1">516 &#x000b1; 34</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Data are means &#x000b1; SE of 8&#x02013;10 mice/group at 6 h after intranasal inoculation of 100 &#x003bc;g lipopolysaccharide from <italic>Klebsiella pneumoniae</italic>. RAGE<sup>-/-</sup>, receptor for advanced glycation end products deficient; SE, standard error; TNF, tumor necrosis factor; IL, interleukin; KC, keratinocyte-derived protein; MIP, macrophage inflammatory protein.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec019"><title>Discussion</title><p><italic>Klebsiella</italic> species is a frequently isolated Gram-negative bacterium in nosocomial as well as in community-acquired pneumonia and in sepsis [<xref rid="pone.0141000.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0141000.ref004" ref-type="bibr">4</xref>] and is associated with high morbidity and mortality. RAGE has the ability to activate signaling pathways, resulting in proinflammatory gene expression upon interaction with several distinct endogenous proinflammatory ligands (DAMPs) [<xref rid="pone.0141000.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0141000.ref007" ref-type="bibr">7</xref>]. Therefore, RAGE may function as a sensor of danger signals leading to a certain amount of inflammation and hence play a beneficial role in bacterial eradication during infection. However, interaction of RAGE with its ligands and the subsequently induced inflammation can also worsen tissue damage, thereby exerting detrimental effects. Our key finding was that RAGE contributes to an effective antibacterial host response during <italic>K</italic>. <italic>pneumoniae</italic> infection. Indeed, RAGE deficiency caused an enhanced outgrowth of <italic>K</italic>. <italic>pneumoniae</italic> at the primary site of infection together with increased spreading of bacteria to other body compartments and an increased mortality. This reduced resistance against <italic>K</italic>. <italic>pneumoniae</italic> in RAGE<sup>-/-</sup> mice could at least in part be explained by a reduced phagocytosis capacity of RAGE<sup>-/-</sup> neutrophils.</p><p>Theoretically, there is a possibility that underlying mechanisms of the increased mortality in the RAGE<sup>-/-</sup> mice were not overt at 24 or 48 hours yet. However, we expect this chance to be small, since the first mice died just a few hours after the 48 hour time point. Therefore, we chose to use 24 and 48 hours as time points to investigate possible underlying mechanisms and not after 48 hours to prevent selection of the surviving mice.</p><p>In our <italic>K</italic>. <italic>pneumoniae</italic> pneumonia model, RAGE<sup>-/-</sup> mice had higher levels of the chemokines KC and MCP-1 in their lung homogenates and increased circulating IL-10 concentrations compared to wild-type mice 48 hours after infection, while intranasal inoculation with LPS from <italic>K</italic>. <italic>pneumoniae</italic> did not lead to higher broncho-alveolar chemokine levels in the RAGE<sup>-/-</sup> mice. The increased chemokine and IL-10 concentrations in the RAGE<sup>-/-</sup> mice in the <italic>K</italic>. <italic>pneumoniae</italic> pneumonia model could in part be due to the increased bacterial load in the RAGE<sup>-/-</sup> mice.</p><p>Our data on the expression of RAGE in the lungs extend earlier reports in finding broad RAGE expression in normal, healthy lungs [<xref rid="pone.0141000.ref031" ref-type="bibr">31</xref>&#x02013;<xref rid="pone.0141000.ref034" ref-type="bibr">34</xref>] and an upregulation of pulmonary RAGE expression during interstitial and postobstructive pneumonia [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>,<xref rid="pone.0141000.ref032" ref-type="bibr">32</xref>]. The present data are in accordance with our recent reports on enhanced RAGE expression in the lungs of mice infected with <italic>S</italic>. <italic>pneumoniae</italic> [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>] or influenza A [<xref rid="pone.0141000.ref037" ref-type="bibr">37</xref>]. In addition, we showed that levels of the RAGE ligand HMGB1 are elevated in BALF during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia, similar to data from mice with intratracheally administered <italic>E</italic>. <italic>coli</italic> induced lung injury [<xref rid="pone.0141000.ref043" ref-type="bibr">43</xref>]. Furthermore, the RAGE ligand S100A12 is released in patients with sepsis [<xref rid="pone.0141000.ref017" ref-type="bibr">17</xref>] and enhanced S100A12 concentrations have been shown in BALF from patients with acute lung injury and from healthy volunteers after LPS inhalation [<xref rid="pone.0141000.ref034" ref-type="bibr">34</xref>], but evidence that a functional <italic>s100a12</italic> gene is not present in the murine genome [<xref rid="pone.0141000.ref044" ref-type="bibr">44</xref>] implies that RAGE-S100A12 ligation does not attribute to the host response to pneumonia in mice.</p><p>The current data should be considered in the context of several other studies on the role of RAGE during bacterial infections. Ramsgaard et al. reported that RAGE deficiency leads to a reduced inflammation after intratracheal administration of <italic>E</italic>. <italic>coli</italic> [<xref rid="pone.0141000.ref043" ref-type="bibr">43</xref>]. Compared to wild-type mice, RAGE<sup>-/-</sup> mice had lower concentrations of neutrophils, protein, MPO, cytokines and chemokines in their BALF. In that study, bacterial outgrowth, dissemination and survival were not reported; therefore the possible role of RAGE in antibacterial defense cannot be determined from this investigation. In a model of polymicrobial abdominal sepsis induced by CLP, RAGE<sup>-/-</sup> mice had an improved survival together with a reduced NF-&#x003ba;B activation in the peritoneum [<xref rid="pone.0141000.ref020" ref-type="bibr">20</xref>,<xref rid="pone.0141000.ref021" ref-type="bibr">21</xref>]. Moreover, anti-RAGE therapy conferred a survival advantage even when administered 24 h after CLP in mice receiving antibiotic treatment [<xref rid="pone.0141000.ref021" ref-type="bibr">21</xref>]. In the latter study, RAGE deficiency or anti-RAGE therapy was reported not to influence bacterial loads in peritoneal lavage fluid, liver or spleen. It should be noted, however, that in this study, all mice were treated with broad spectrum antibiotics and bacterial loads were only determined in mice that survived (<italic>i</italic>.<italic>e</italic>. not at predefined time points after CLP induction). We previously investigated the role of RAGE during abdominal sepsis induced by <italic>E</italic>. <italic>coli</italic>, showing that RAGE deficiency was associated with an enhanced outgrowth of <italic>E</italic>. <italic>coli</italic> locally and in distant organs together with more severe liver injury [<xref rid="pone.0141000.ref022" ref-type="bibr">22</xref>]. In contrast, in a model of Gram-positive pneumonia caused by <italic>S</italic>. <italic>pneumoniae</italic>, RAGE deficiency was associated with a reduced bacterial outgrowth and dissemination and less severe lung damage [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>]. Interestingly, Christaki et al demonstrated that treatment with anti-RAGE antibodies combined with the antibiotic moxifloxacin protects mice from <italic>S</italic>. <italic>pneumoniae</italic> pneumonia induced mortality [<xref rid="pone.0141000.ref024" ref-type="bibr">24</xref>].</p><p>One possible explanation for the intriguing observation that RAGE involvement during (Gram-positive) pneumococcal and (Gram-negative) <italic>Klebsiella</italic> pneumonia has opposite effects on bacterial clearance and mortality is that RAGE mediated effects on first-line defense mechanisms may depend on the pathogen. <italic>In vitro</italic> phagocytosis of <italic>Klebsiella</italic> bacteria was decreased in the RAGE<sup>-/-</sup> neutrophils, which could at least partly account for the higher bacterial loads in the RAGE<sup>-/-</sup> mice. Of considerable interest, a study identified RAGE as a receptor for LPS derived from various Gram-negative bacteria, including <italic>K</italic>. <italic>pneumoniae</italic> [<xref rid="pone.0141000.ref045" ref-type="bibr">45</xref>]. These authors reported reduced LPS responsiveness of RAGE<sup>-/-</sup> peritoneal macrophages <italic>in vitro</italic> and attenuated cytokine release and mortality in RAGE<sup>-/-</sup> mice after intraperitoneal LPS injection <italic>in vivo</italic> [<xref rid="pone.0141000.ref045" ref-type="bibr">45</xref>]. We also previously demonstrated attenuated systemic TNF-&#x003b1; release upon intraperitoneal LPS administration to RAGE<sup>-/-</sup> mice when compared to wild-type mice [<xref rid="pone.0141000.ref022" ref-type="bibr">22</xref>]. We here could not establish a role for RAGE in inflammation produced by intrapulmonary delivery of LPS. Together these data suggest that the contribution of RAGE to LPS responses <italic>in vivo</italic> depends on the body compartment and further indicate that the role of RAGE in antibacterial defense likely at least in part relies on the specific microorganism and the pathogen-associated molecular patterns they express.</p><p>Efferocytosis (the clearance of apoptotic cells via ingestion of apoptotic cells by macrophages and other phagocytic cells) is a major mechanism for the resolution of inflammation [<xref rid="pone.0141000.ref046" ref-type="bibr">46</xref>]. Of note, our laboratory demonstrated that during pneumonia, alveolar macophages are indispensable in the host response by means of their capacity to modulate inflammation via elimination of apoptotic neutrophils [<xref rid="pone.0141000.ref047" ref-type="bibr">47</xref>]. Previously, it was reported that RAGE participates in efferocytosis through binding to phosphatidylserine, the &#x0201c;eat me&#x0201d; signal highly expressed on apoptotic cells [<xref rid="pone.0141000.ref048" ref-type="bibr">48</xref>]. The lack of RAGE resulted in a decreased ability to engulf apoptotic cells <italic>in vitro</italic> and <italic>in vivo</italic> [<xref rid="pone.0141000.ref046" ref-type="bibr">46</xref>]. In our experiments, lung inflammation did not differ between the two mouse strains. In this context it is important to emphasize that the efferocytosis investigations were performed during sterile conditions. In our pneumonia model, the higher bacterial loads might have overruled this effect of RAGE deficiency, resulting in net similar lung inflammation and damage in the the lungs of RAGE<sup>-/-</sup> mice compared with that of the wild-type mice.</p><p>The recruitment of neutrophils is an important part of host defense against pneumonia [<xref rid="pone.0141000.ref049" ref-type="bibr">49</xref>]. RAGE has been implicated in the regulation of cell migration. Indeed, RAGE<sup>-/-</sup> mice had a lower number of adherent inflammatory cells on the peritoneum after CLP [<xref rid="pone.0141000.ref020" ref-type="bibr">20</xref>] and a reduction in neutrophil influx in the peritoneal cavity during thioglycollate peritonitis [<xref rid="pone.0141000.ref019" ref-type="bibr">19</xref>]. Furthermore, <italic>in vivo</italic> studies have suggested that RAGE is an endothelial counter receptor for the &#x003b2;2 integrin Mac-1 [<xref rid="pone.0141000.ref019" ref-type="bibr">19</xref>,<xref rid="pone.0141000.ref050" ref-type="bibr">50</xref>]. During pneumococcal pneumonia RAGE<sup>-/-</sup> mice showed an attenuated influx of neutrophils into the lungs together with a decreased pneumococcal load [<xref rid="pone.0141000.ref023" ref-type="bibr">23</xref>]. Intratracheal delivered <italic>E</italic>. <italic>coli</italic> in mice resulted in lower neutrophil and MPO concentrations in BALF from RAGE<sup>-/-</sup> mice [<xref rid="pone.0141000.ref043" ref-type="bibr">43</xref>]. Since CFUs were not reported in that study, it is not known whether the reduced neutrophil influx is at least in part due to a lower bacterial load. In contrast, we did not find an effect of RAGE deficiency on cell influx during <italic>K</italic>. <italic>pneumoniae</italic> pneumonia, as indicated by histopathology and pulmonary MPO concentrations. Moreover, leukocyte counts and differentials in BALF harvested after intrapulmonary delivery of <italic>Klebsiella</italic> LPS were similar in wild-type and RAGE<sup>-/-</sup> mice which is in line with results of experiments with intratracheal administration of LPS from <italic>E</italic>. <italic>coli</italic> [<xref rid="pone.0141000.ref043" ref-type="bibr">43</xref>]. Together these data suggest that RAGE does not play a role of importance in leukocyte recruitment to the lungs during <italic>K</italic>. <italic>pneumoniae</italic> infection, and that the impact of RAGE on cell trafficking may depend on the inflammatory stimulus and the organ involved.</p><p>The current study is the first to establish that RAGE is important for antibacterial defense against <italic>Klebsiella</italic> pneumonia. We here show that RAGE plays a protective role during respiratory tract infection by a common Gram-negative causative pathogen, <italic>K</italic>. <italic>pneumoniae</italic>, by improving antibacterial defense in lungs and reducing bacterial dissemination. This could at least in part be explained by a better phagocytosis capacity of neutrophils in the presence of RAGE. Moreover, our results document that RAGE is not essential for the induction of excessive lung inflammation and injury.</p></sec></body><back><ack><p>We thank Joost Daalhuisen and Marieke S. ten Brink for expert technical assistance.</p><p>This work has been awarded with the IDSA/ID-week International Investigator Award 2012 (to dr. M.A.D. van Zoelen).</p><p>Part of the information in this manuscript has been presented orally by dr. M.A.D. van Zoelen at the 14<sup>th</sup> European Congress on Internal Medicine, Moscow 2015 and at the Infectious Diseases Society of America (IDSA) ID-week, San Diego 2012 and as an abstract at the The Merinoff World Congress 2013: HMGB1, Manhasset, NY 2013.</p></ack><ref-list><title>References</title><ref id="pone.0141000.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Kollef</surname><given-names>MH</given-names></name>, <name><surname>Kollef</surname><given-names>KE</given-names></name> (<year>2005</year>) <article-title>Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results</article-title>. <source>Chest</source>
<volume>128</volume>: <fpage>2706</fpage>&#x02013;<lpage>2713</lpage>. <pub-id pub-id-type="pmid">16236946</pub-id></mixed-citation></ref><ref id="pone.0141000.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Podschun</surname><given-names>R</given-names></name>, <name><surname>Ullmann</surname><given-names>U</given-names></name> (<year>1998</year>) <article-title>Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors</article-title>. <source>Clin Microbiol Rev</source>
<volume>11</volume>: <fpage>589</fpage>&#x02013;<lpage>603</lpage>. <pub-id pub-id-type="pmid">9767057</pub-id></mixed-citation></ref><ref id="pone.0141000.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>CI</given-names></name>, <name><surname>Song</surname><given-names>JH</given-names></name>, <name><surname>Chung</surname><given-names>DR</given-names></name>, <name><surname>Peck</surname><given-names>KR</given-names></name>, <name><surname>Ko</surname><given-names>KS</given-names></name>, <name><surname>Yeom</surname><given-names>JS</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Risk factors and pathogenic significance of severe sepsis and septic shock in 2286 patients with gram-negative bacteremia</article-title>. <source>J Infect</source>
<volume>62</volume>: <fpage>26</fpage>&#x02013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2010.10.010</pub-id>
<pub-id pub-id-type="pmid">21056057</pub-id></mixed-citation></ref><ref id="pone.0141000.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Shorr</surname><given-names>AF</given-names></name>, <name><surname>Tabak</surname><given-names>YP</given-names></name>, <name><surname>Killian</surname><given-names>AD</given-names></name>, <name><surname>Gupta</surname><given-names>V</given-names></name>, <name><surname>Liu</surname><given-names>LZ</given-names></name>, <name><surname>Kollef</surname><given-names>MH</given-names></name> (<year>2006</year>) <article-title>Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database</article-title>. <source>Crit Care Med</source>
<volume>34</volume>: <fpage>2588</fpage>&#x02013;<lpage>2595</lpage>. <pub-id pub-id-type="pmid">16915117</pub-id></mixed-citation></ref><ref id="pone.0141000.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Giamarellou</surname><given-names>H</given-names></name> (<year>2005</year>) <article-title>Multidrug resistance in Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs)</article-title>. <source>Clin Microbiol Infect</source>
<volume>11</volume>
<issue>Suppl 4</issue>: <fpage>1</fpage>&#x02013;<lpage>16</lpage>. <pub-id pub-id-type="pmid">15953019</pub-id></mixed-citation></ref><ref id="pone.0141000.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Christaki</surname><given-names>E</given-names></name>, <name><surname>Lazaridis</surname><given-names>N</given-names></name>, <name><surname>Opal</surname><given-names>SM</given-names></name> (<year>2012</year>) <article-title>Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?</article-title>
<source>Curr Opin Infect Dis</source>
<volume>25</volume>: <fpage>304</fpage>&#x02013;<lpage>311</lpage>. <pub-id pub-id-type="pmid">22327468</pub-id></mixed-citation></ref><ref id="pone.0141000.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Achouiti</surname><given-names>A</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name> (<year>2011</year>) <article-title>The role of receptor for advanced glycation endproducts (RAGE) in infection</article-title>. <source>Crit Care</source>
<volume>15</volume>: <fpage>208</fpage>
<pub-id pub-id-type="doi">10.1186/cc9990</pub-id>
<pub-id pub-id-type="pmid">21457506</pub-id></mixed-citation></ref><ref id="pone.0141000.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Bianchi</surname><given-names>ME</given-names></name> (<year>2007</year>) <article-title>DAMPs, PAMPs and alarmins: all we need to know about danger</article-title>. <source>J Leukoc Biol</source>
<volume>81</volume>: <fpage>1</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0141000.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Huttunen</surname><given-names>HJ</given-names></name>, <name><surname>Fages</surname><given-names>C</given-names></name>, <name><surname>Rauvala</surname><given-names>H</given-names></name> (<year>1999</year>) <article-title>Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways</article-title>. <source>J Biol Chem</source>
<volume>274</volume>: <fpage>19919</fpage>&#x02013;<lpage>19924</lpage>. <pub-id pub-id-type="pmid">10391939</pub-id></mixed-citation></ref><ref id="pone.0141000.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>R</given-names></name>, <name><surname>Mori</surname><given-names>S</given-names></name>, <name><surname>Wake</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Liu</surname><given-names>K</given-names></name>, <name><surname>Izushi</surname><given-names>Y</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Establishment of in vitro binding assay of high mobility group box-1 and S100A12 to receptor for advanced glycation endproducts: heparin's effect on binding</article-title>. <source>Acta Med Okayama</source>
<volume>63</volume>: <fpage>203</fpage>&#x02013;<lpage>211</lpage>. <pub-id pub-id-type="pmid">19727205</pub-id></mixed-citation></ref><ref id="pone.0141000.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Srikrishna</surname><given-names>G</given-names></name>, <name><surname>Nayak</surname><given-names>J</given-names></name>, <name><surname>Weigle</surname><given-names>B</given-names></name>, <name><surname>Temme</surname><given-names>A</given-names></name>, <name><surname>Foell</surname><given-names>D</given-names></name>, <name><surname>Hazelwood</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Carboxylated N-glycans on RAGE promote S100A12 binding and signaling</article-title>. <source>J Cell Biochem</source>
<volume>110</volume>: <fpage>645</fpage>&#x02013;<lpage>659</lpage>. <pub-id pub-id-type="doi">10.1002/jcb.22575</pub-id>
<pub-id pub-id-type="pmid">20512925</pub-id></mixed-citation></ref><ref id="pone.0141000.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Xie</surname><given-names>J</given-names></name>, <name><surname>Burz</surname><given-names>DS</given-names></name>, <name><surname>He</surname><given-names>W</given-names></name>, <name><surname>Bronstein</surname><given-names>IB</given-names></name>, <name><surname>Lednev</surname><given-names>I</given-names></name>, <name><surname>Shekhtman</surname><given-names>A</given-names></name> (<year>2007</year>) <article-title>Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches</article-title>. <source>J Biol Chem</source>
<volume>282</volume>: <fpage>4218</fpage>&#x02013;<lpage>4231</lpage>. <pub-id pub-id-type="pmid">17158877</pub-id></mixed-citation></ref><ref id="pone.0141000.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Bloom</surname><given-names>O</given-names></name>, <name><surname>Zhang</surname><given-names>M</given-names></name>, <name><surname>Vishnubhakat</surname><given-names>JM</given-names></name>, <name><surname>Ombrellino</surname><given-names>M</given-names></name>, <name><surname>Che</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>HMG-1 as a late mediator of endotoxin lethality in mice</article-title>. <source>Science</source>
<volume>285</volume>: <fpage>248</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="pmid">10398600</pub-id></mixed-citation></ref><ref id="pone.0141000.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Sunden-Cullberg</surname><given-names>J</given-names></name>, <name><surname>Norrby-Teglund</surname><given-names>A</given-names></name>, <name><surname>Rouhiainen</surname><given-names>A</given-names></name>, <name><surname>Rauvala</surname><given-names>H</given-names></name>, <name><surname>Herman</surname><given-names>G</given-names></name>, <name><surname>Tracey</surname><given-names>KJ</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Persistent elevation of high mobility group box-1 protein (HMGB1) in patients with severe sepsis and septic shock</article-title>. <source>Crit Care Med</source>
<volume>33</volume>: <fpage>564</fpage>&#x02013;<lpage>573</lpage>. <pub-id pub-id-type="pmid">15753748</pub-id></mixed-citation></ref><ref id="pone.0141000.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Ueno</surname><given-names>H</given-names></name>, <name><surname>Matsuda</surname><given-names>T</given-names></name>, <name><surname>Hashimoto</surname><given-names>S</given-names></name>, <name><surname>Amaya</surname><given-names>F</given-names></name>, <name><surname>Kitamura</surname><given-names>Y</given-names></name>, <name><surname>Tanaka</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Contributions of high mobility group box protein in experimental and clinical acute lung injury</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>170</volume>: <fpage>1310</fpage>&#x02013;<lpage>1316</lpage>. <pub-id pub-id-type="pmid">15374839</pub-id></mixed-citation></ref><ref id="pone.0141000.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Laterre</surname><given-names>PF</given-names></name>, <name><surname>van Veen</surname><given-names>SQ</given-names></name>, <name><surname>van Till</surname><given-names>JW</given-names></name>, <name><surname>Wittebole</surname><given-names>X</given-names></name>, <name><surname>Bresser</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Systemic and local high mobility group box 1 concentrations during severe infection</article-title>. <source>Crit Care Med</source>
<volume>35</volume>: <fpage>2799</fpage>&#x02013;<lpage>2804</lpage>. <pub-id pub-id-type="pmid">17901841</pub-id></mixed-citation></ref><ref id="pone.0141000.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Foell</surname><given-names>DMD</given-names></name>, <name><surname>Wittkowski</surname><given-names>H</given-names></name>, <name><surname>Kessel</surname><given-names>C</given-names></name>, <name><surname>Luken</surname><given-names>A</given-names></name>, <name><surname>Weinhage</surname><given-names>T</given-names></name>, <name><surname>Varga</surname><given-names>G</given-names></name>, et el. (<year>2013</year>) <article-title>Pro-inflammatory S100A12 can Activate Human Monocytes via Toll-like Receptor 4</article-title>. <source>Am J Respir Crit Care Med</source>.</mixed-citation></ref><ref id="pone.0141000.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Achouiti</surname><given-names>A</given-names></name>, <name><surname>Schmidt</surname><given-names>AM</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Tracey</surname><given-names>KJ</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Ligands of the receptor for advanced glycation end products, including high-mobility group box 1, limit bacterial dissemination during Escherichia coli peritonitis</article-title>. <source>Crit Care Med</source>.</mixed-citation></ref><ref id="pone.0141000.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Chavakis</surname><given-names>T</given-names></name>, <name><surname>Bierhaus</surname><given-names>A</given-names></name>, <name><surname>Al Fakhri</surname><given-names>N</given-names></name>, <name><surname>Schneider</surname><given-names>D</given-names></name>, <name><surname>Witte</surname><given-names>S</given-names></name>, <name><surname>Linn</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment</article-title>. <source>J Exp Med</source>
<volume>198</volume>: <fpage>1507</fpage>&#x02013;<lpage>1515</lpage>. <pub-id pub-id-type="pmid">14623906</pub-id></mixed-citation></ref><ref id="pone.0141000.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Liliensiek</surname><given-names>B</given-names></name>, <name><surname>Weigand</surname><given-names>MA</given-names></name>, <name><surname>Bierhaus</surname><given-names>A</given-names></name>, <name><surname>Nicklas</surname><given-names>W</given-names></name>, <name><surname>Kasper</surname><given-names>M</given-names></name>, <name><surname>Hofer</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response</article-title>. <source>J Clin Invest</source>
<volume>113</volume>: <fpage>1641</fpage>&#x02013;<lpage>1650</lpage>. <pub-id pub-id-type="pmid">15173891</pub-id></mixed-citation></ref><ref id="pone.0141000.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Lutterloh</surname><given-names>EC</given-names></name>, <name><surname>Opal</surname><given-names>SM</given-names></name>, <name><surname>Pittman</surname><given-names>DD</given-names></name>, <name><surname>Keith</surname><given-names>JC</given-names><suffix>Jr</suffix></name>, <name><surname>Tan</surname><given-names>XY</given-names></name>, <name><surname>Clancy</surname><given-names>BM</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection</article-title>. <source>Crit Care</source>
<volume>11</volume>: <fpage>R122</fpage>
<pub-id pub-id-type="pmid">18042296</pub-id></mixed-citation></ref><ref id="pone.0141000.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Schmidt</surname><given-names>AM</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Meijers</surname><given-names>JC</given-names></name>, <name><surname>de Beer</surname><given-names>R</given-names></name>, <name><surname>de Vos</surname><given-names>AF</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Receptor for advanced glycation end products facilitates host defense during Escherichia coli-induced abdominal sepsis in mice</article-title>. <source>J Infect Dis</source>
<volume>200</volume>: <fpage>765</fpage>&#x02013;<lpage>773</lpage>. <pub-id pub-id-type="doi">10.1086/604730</pub-id>
<pub-id pub-id-type="pmid">19627249</pub-id></mixed-citation></ref><ref id="pone.0141000.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Schouten</surname><given-names>M</given-names></name>, <name><surname>de Vos</surname><given-names>AF</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Meijers</surname><given-names>JC</given-names></name>, <name><surname>Nawroth</surname><given-names>PP</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>The receptor for advanced glycation end products impairs host defense in pneumococcal pneumonia</article-title>. <source>J Immunol</source>
<volume>182</volume>: <fpage>4349</fpage>&#x02013;<lpage>4356</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0801199</pub-id>
<pub-id pub-id-type="pmid">19299735</pub-id></mixed-citation></ref><ref id="pone.0141000.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Christaki</surname><given-names>E</given-names></name>, <name><surname>Opal</surname><given-names>SM</given-names></name>, <name><surname>Keith</surname><given-names>JC</given-names><suffix>Jr</suffix></name>, <name><surname>Kessimian</surname><given-names>N</given-names></name>, <name><surname>Palardy</surname><given-names>JE</given-names></name>, <name><surname>Parejo</surname><given-names>NA</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia</article-title>. <source>Shock</source>
<volume>35</volume>: <fpage>492</fpage>&#x02013;<lpage>498</lpage>. <pub-id pub-id-type="pmid">21263385</pub-id></mixed-citation></ref><ref id="pone.0141000.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Bartlett</surname><given-names>JG</given-names></name>, <name><surname>Mundy</surname><given-names>LM</given-names></name> (<year>1995</year>) <article-title>Community-acquired pneumonia</article-title>. <source>N Engl J Med</source>
<volume>333</volume>: <fpage>1618</fpage>&#x02013;<lpage>1624</lpage>. <pub-id pub-id-type="pmid">7477199</pub-id></mixed-citation></ref><ref id="pone.0141000.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>PD</given-names></name>, <name><surname>Lerner</surname><given-names>SA</given-names></name> (<year>1998</year>) <article-title>Community-acquired pneumonia</article-title>. <source>Lancet</source>
<volume>352</volume>: <fpage>1295</fpage>&#x02013;<lpage>1302</lpage>. <pub-id pub-id-type="pmid">9788476</pub-id></mixed-citation></ref><ref id="pone.0141000.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Constien</surname><given-names>R</given-names></name>, <name><surname>Forde</surname><given-names>A</given-names></name>, <name><surname>Liliensiek</surname><given-names>B</given-names></name>, <name><surname>Grone</surname><given-names>HJ</given-names></name>, <name><surname>Nawroth</surname><given-names>P</given-names></name>, <name><surname>Hammerling</surname><given-names>G</given-names></name>, <etal>et al</etal> (<year>2001</year>) <article-title>Characterization of a novel EGFP reporter mouse to monitor Cre recombination as demonstrated by a Tie2 Cre mouse line</article-title>. <source>Genesis</source>
<volume>30</volume>: <fpage>36</fpage>&#x02013;<lpage>44</lpage>. <pub-id pub-id-type="pmid">11353516</pub-id></mixed-citation></ref><ref id="pone.0141000.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Renckens</surname><given-names>R</given-names></name>, <name><surname>Roelofs</surname><given-names>JJ</given-names></name>, <name><surname>Bonta</surname><given-names>PI</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>de Vries</surname><given-names>CJ</given-names></name>, <name><surname>Levi</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Plasminogen activator inhibitor type 1 is protective during severe Gram-negative pneumonia</article-title>. <source>Blood</source>
<volume>109</volume>: <fpage>1593</fpage>&#x02013;<lpage>1601</lpage>. <pub-id pub-id-type="pmid">17032919</pub-id></mixed-citation></ref><ref id="pone.0141000.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>van der Windt</surname><given-names>GJ</given-names></name>, <name><surname>Hoogerwerf</surname><given-names>JJ</given-names></name>, <name><surname>de Vos</surname><given-names>AF</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name> (<year>2010</year>) <article-title>Osteopontin promotes host defense during Klebsiella pneumoniae-induced pneumonia</article-title>. <source>Eur Respir J</source>.</mixed-citation></ref><ref id="pone.0141000.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Wiersinga</surname><given-names>WJ</given-names></name>, <name><surname>Wieland</surname><given-names>CW</given-names></name>, <name><surname>Roelofs</surname><given-names>JJ</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name> (<year>2008</year>) <article-title>MyD88 dependent signaling contributes to protective host defense against Burkholderia pseudomallei</article-title>. <source>PLoS One</source>
<volume>3</volume>: <fpage>e3494</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0003494</pub-id>
<pub-id pub-id-type="pmid">18946505</pub-id></mixed-citation></ref><ref id="pone.0141000.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Cheng</surname><given-names>C</given-names></name>, <name><surname>Tsuneyama</surname><given-names>K</given-names></name>, <name><surname>Kominami</surname><given-names>R</given-names></name>, <name><surname>Shinohara</surname><given-names>H</given-names></name>, <name><surname>Sakurai</surname><given-names>S</given-names></name>, <name><surname>Yonekura</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs</article-title>. <source>Mod Pathol</source>
<volume>18</volume>: <fpage>1385</fpage>&#x02013;<lpage>1396</lpage>. <pub-id pub-id-type="pmid">15933755</pub-id></mixed-citation></ref><ref id="pone.0141000.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Morbini</surname><given-names>P</given-names></name>, <name><surname>Villa</surname><given-names>C</given-names></name>, <name><surname>Campo</surname><given-names>I</given-names></name>, <name><surname>Zorzetto</surname><given-names>M</given-names></name>, <name><surname>Inghilleri</surname><given-names>S</given-names></name>, <name><surname>Luisetti</surname><given-names>M</given-names></name> (<year>2006</year>) <article-title>The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?</article-title>
<source>Mod Pathol</source>
<volume>19</volume>: <fpage>1437</fpage>&#x02013;<lpage>1445</lpage>. <pub-id pub-id-type="pmid">16941014</pub-id></mixed-citation></ref><ref id="pone.0141000.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Uchida</surname><given-names>T</given-names></name>, <name><surname>Shirasawa</surname><given-names>M</given-names></name>, <name><surname>Ware</surname><given-names>LB</given-names></name>, <name><surname>Kojima</surname><given-names>K</given-names></name>, <name><surname>Hata</surname><given-names>Y</given-names></name>, <name><surname>Makita</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>173</volume>: <fpage>1008</fpage>&#x02013;<lpage>1015</lpage>. <pub-id pub-id-type="pmid">16456142</pub-id></mixed-citation></ref><ref id="pone.0141000.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Wittkowski</surname><given-names>H</given-names></name>, <name><surname>Sturrock</surname><given-names>A</given-names></name>, <name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Viemann</surname><given-names>D</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name>, <name><surname>Hoidal</surname><given-names>JR</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome</article-title>. <source>Crit Care Med</source>
<volume>35</volume>: <fpage>1369</fpage>&#x02013;<lpage>1375</lpage>. <pub-id pub-id-type="pmid">17414728</pub-id></mixed-citation></ref><ref id="pone.0141000.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Sorci</surname><given-names>G</given-names></name>, <name><surname>Riuzzi</surname><given-names>F</given-names></name>, <name><surname>Arcuri</surname><given-names>C</given-names></name>, <name><surname>Giambanco</surname><given-names>I</given-names></name>, <name><surname>Donato</surname><given-names>R</given-names></name> (<year>2004</year>) <article-title>Amphoterin stimulates myogenesis and counteracts the antimyogenic factors basic fibroblast growth factor and S100B via RAGE binding</article-title>. <source>Mol Cell Biol</source>
<volume>24</volume>: <fpage>4880</fpage>&#x02013;<lpage>4894</lpage>. <pub-id pub-id-type="pmid">15143181</pub-id></mixed-citation></ref><ref id="pone.0141000.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>Ishizaka</surname><given-names>A</given-names></name>, <name><surname>Wolthuls</surname><given-names>EK</given-names></name>, <name><surname>Choi</surname><given-names>G</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name>, <name><surname>Schultz</surname><given-names>MJ</given-names></name> (<year>2008</year>) <article-title>Pulmonary levels of high-mobility group box 1 during mechanical ventilation and ventilator-associated pneumonia</article-title>. <source>Shock</source>
<volume>29</volume>: <fpage>441</fpage>&#x02013;<lpage>445</lpage>. <pub-id pub-id-type="pmid">18344842</pub-id></mixed-citation></ref><ref id="pone.0141000.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>van Zoelen</surname><given-names>MA</given-names></name>, <name><surname>van der Sluijs</surname><given-names>KF</given-names></name>, <name><surname>Achouiti</surname><given-names>A</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Braun-Pater</surname><given-names>JM</given-names></name>, <name><surname>Yang</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Receptor for advanced glycation end products is detrimental during influenza A virus pneumonia</article-title>. <source>Virology</source>
<volume>391</volume>: <fpage>265</fpage>&#x02013;<lpage>273</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2009.05.032</pub-id>
<pub-id pub-id-type="pmid">19592063</pub-id></mixed-citation></ref><ref id="pone.0141000.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Knapp</surname><given-names>S</given-names></name>, <name><surname>Schultz</surname><given-names>MJ</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Pneumonia models and innate immunity to respiratory bacterial pathogens</article-title>. <source>Shock</source>
<volume>24</volume>
<issue>Suppl 1</issue>: <fpage>12</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="pmid">16374367</pub-id></mixed-citation></ref><ref id="pone.0141000.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Strieter</surname><given-names>RM</given-names></name>, <name><surname>Belperio</surname><given-names>JA</given-names></name>, <name><surname>Keane</surname><given-names>MP</given-names></name> (<year>2003</year>) <article-title>Host innate defenses in the lung: the role of cytokines</article-title>. <source>Curr Opin Infect Dis</source>
<volume>16</volume>: <fpage>193</fpage>&#x02013;<lpage>198</lpage>. <pub-id pub-id-type="pmid">12821807</pub-id></mixed-citation></ref><ref id="pone.0141000.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Rijneveld</surname><given-names>AW</given-names></name>, <name><surname>Weijer</surname><given-names>S</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Esmon</surname><given-names>CT</given-names></name>, <name><surname>Meijers</surname><given-names>JC</given-names></name>, <name><surname>Speelman</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Thrombomodulin mutant mice with a strongly reduced capacity to generate activated protein C have an unaltered pulmonary immune response to respiratory pathogens and lipopolysaccharide</article-title>. <source>Blood</source>
<volume>103</volume>: <fpage>1702</fpage>&#x02013;<lpage>1709</lpage>. <pub-id pub-id-type="pmid">14592828</pub-id></mixed-citation></ref><ref id="pone.0141000.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Leemans</surname><given-names>JC</given-names></name>, <name><surname>Vervoordeldonk</surname><given-names>MJ</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>van Kessel</surname><given-names>KP</given-names></name>, <name><surname>van der Poll</surname><given-names>T</given-names></name> (<year>2002</year>) <article-title>Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>165</volume>: <fpage>1445</fpage>&#x02013;<lpage>1450</lpage>. <pub-id pub-id-type="pmid">12016110</pub-id></mixed-citation></ref><ref id="pone.0141000.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Knapp</surname><given-names>S</given-names></name>, <name><surname>von Aulock</surname><given-names>S</given-names></name>, <name><surname>Leendertse</surname><given-names>M</given-names></name>, <name><surname>Haslinger</surname><given-names>I</given-names></name>, <name><surname>Draing</surname><given-names>C</given-names></name>, <name><surname>Golenbock</surname><given-names>DT</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor</article-title>. <source>J Immunol</source>
<volume>180</volume>: <fpage>3478</fpage>&#x02013;<lpage>3484</lpage>. <pub-id pub-id-type="pmid">18292574</pub-id></mixed-citation></ref><ref id="pone.0141000.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Ramsgaard</surname><given-names>L</given-names></name>, <name><surname>Englert</surname><given-names>JM</given-names></name>, <name><surname>Manni</surname><given-names>ML</given-names></name>, <name><surname>Milutinovic</surname><given-names>PS</given-names></name>, <name><surname>Gefter</surname><given-names>J</given-names></name>, <name><surname>Tobolewski</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Lack of the Receptor for Advanced Glycation End-Products Attenuates E. coli Pneumonia in Mice</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e20132</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0020132</pub-id>
<pub-id pub-id-type="pmid">21629785</pub-id></mixed-citation></ref><ref id="pone.0141000.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Fuellen</surname><given-names>G</given-names></name>, <name><surname>Foell</surname><given-names>D</given-names></name>, <name><surname>Nacken</surname><given-names>W</given-names></name>, <name><surname>Sorg</surname><given-names>C</given-names></name>, <name><surname>Kerkhoff</surname><given-names>C</given-names></name> (<year>2003</year>) <article-title>Absence of S100A12 in mouse: implications for RAGE-S100A12 interaction</article-title>. <source>Trends Immunol</source>
<volume>24</volume>: <fpage>622</fpage>&#x02013;<lpage>624</lpage>. <pub-id pub-id-type="pmid">14644132</pub-id></mixed-citation></ref><ref id="pone.0141000.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>Y</given-names></name>, <name><surname>Harashima</surname><given-names>A</given-names></name>, <name><surname>Saito</surname><given-names>H</given-names></name>, <name><surname>Tsuneyama</surname><given-names>K</given-names></name>, <name><surname>Munesue</surname><given-names>S</given-names></name>, <name><surname>Motoyoshi</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Septic shock is associated with receptor for advanced glycation end products ligation of LPS</article-title>. <source>J Immunol</source>
<volume>186</volume>: <fpage>3248</fpage>&#x02013;<lpage>3257</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1002253</pub-id>
<pub-id pub-id-type="pmid">21270403</pub-id></mixed-citation></ref><ref id="pone.0141000.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Haslett</surname><given-names>C</given-names></name> (<year>1999</year>) <article-title>Granulocyte apoptosis and its role in the resolution and control of lung inflammation</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>160</volume>: <fpage>S5</fpage>&#x02013;<lpage>11</lpage>. <pub-id pub-id-type="pmid">10556161</pub-id></mixed-citation></ref><ref id="pone.0141000.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Knapp</surname><given-names>S</given-names></name>, <name><surname>Leemans</surname><given-names>JC</given-names></name>, <name><surname>Florquin</surname><given-names>S</given-names></name>, <name><surname>Branger</surname><given-names>J</given-names></name>, <name><surname>Maris</surname><given-names>NA</given-names></name>, <name><surname>Pater</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Alveolar macrophages have a protective antiinflammatory role during murine pneumococcal pneumonia</article-title>. <source>Am J Respir Crit Care Med</source>
<volume>167</volume>: <fpage>171</fpage>&#x02013;<lpage>179</lpage>. <pub-id pub-id-type="pmid">12406830</pub-id></mixed-citation></ref><ref id="pone.0141000.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Friggeri</surname><given-names>A</given-names></name>, <name><surname>Banerjee</surname><given-names>S</given-names></name>, <name><surname>Biswas</surname><given-names>S</given-names></name>, <name><surname>de Freitas</surname><given-names>A</given-names></name>, <name><surname>Liu</surname><given-names>G</given-names></name>, <name><surname>Bierhaus</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Participation of the receptor for advanced glycation end products in efferocytosis</article-title>. <source>J Immunol</source>
<volume>186</volume>: <fpage>6191</fpage>&#x02013;<lpage>6198</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1004134</pub-id>
<pub-id pub-id-type="pmid">21502377</pub-id></mixed-citation></ref><ref id="pone.0141000.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Strieter</surname><given-names>RM</given-names></name>, <name><surname>Belperio</surname><given-names>JA</given-names></name>, <name><surname>Keane</surname><given-names>MP</given-names></name> (<year>2002</year>) <article-title>Cytokines in innate host defense in the lung</article-title>. <source>J Clin Invest</source>
<volume>109</volume>: <fpage>699</fpage>&#x02013;<lpage>705</lpage>. <pub-id pub-id-type="pmid">11901175</pub-id></mixed-citation></ref><ref id="pone.0141000.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Zen</surname><given-names>K</given-names></name>, <name><surname>Chen</surname><given-names>CX</given-names></name>, <name><surname>Chen</surname><given-names>YT</given-names></name>, <name><surname>Wilton</surname><given-names>R</given-names></name>, <name><surname>Liu</surname><given-names>Y</given-names></name> (<year>2007</year>) <article-title>Receptor for advanced glycation endproducts mediates neutrophil migration across intestinal epithelium</article-title>. <source>J Immunol</source>
<volume>178</volume>: <fpage>2483</fpage>&#x02013;<lpage>2490</lpage>. <pub-id pub-id-type="pmid">17277156</pub-id></mixed-citation></ref></ref-list></back></article>